Guggenheim initiated coverage of Lexeo Therapeutics (LXEO) with a Buy rating and $30 price target
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LXEO:
- Buy Rating for Lexeo Therapeutics Driven by Regulatory Progress and Promising Clinical Data on LX2006
- Lexeo Therapeutics price target raised to $17 from $15 at Chardan
- IBM partners with Anthropic, Dell boosts long-term view: Morning Buzz
- Lexeo Therapeutics price target raised to $15 from $9 at H.C. Wainwright
- Positive Outlook for Lexeo Therapeutics: Regulatory Advancements and Promising LX2006 Data Boost Stock Target